Nestlé Nutrition Corporate is starting in Phage Therapy trials

Antibacterial Treatment Against Diarrhea in Oral Rehydration Solution
(by T4 phage)

Randomized, Double Blind Placebo-controlled Studies to Evaluate the Effect of an Orally-fed Escherichia Coli (E. Coli) Phage in the Management of ETEC and EPEC Induced Diarrhea in Children.

This study hopes to demonstrate the potentials of a new form of therapy for childhood diarrhea, a major cause of morbidity and deaths in Bangladesh and other developing countries, and thus a priority for improving child health.



Scientific works:


T4 phages against Escherichia coli diarrhea: Potential and problems
Nestle´ Research Centre, CH-1000 Lausanne 26 Vers-chez-les-Blanc, Switzerland

Phage therapy: the Escherichia coli experience
Harald Brüssow
Nestle´ Research Centre, CH-1000 Lausanne 26 Vers-chez-les-Blanc, Switzerland

Human Volunteers Receiving Escherichia coli Phage T4 Orally:
a Safety Test of Phage Therapy
Anne Bruttin and Harald Brüssow,
Nestle´ Research Center, Nestec Ltd., Vers-chez-les-Blanc, CH-1000 Lausanne 26, Switzerland